Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,511 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Post-Traumatic Stress Disorder, Acute Respiratory Failure
Interventions: Ketamine, Etomidate; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 3 more

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma
Interventions: Educational Intervention, Electronic Health Record Review, Follow-Up, Internet-Based Intervention, Interview, Survey Administration; Other · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Kidney Transplant Recipients, Liver Transplant Recipients
Interventions: Prograf, Tacrolimus; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ketoconazole, casopitant 100 mg, Casopitant 50 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Central Nervous System
Interventions: NIH Toolbox Cognitive Battery; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 5 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Healthy Volunteer
Interventions: Pirfenidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: CP, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic
Interventions: Whole body vibration training; Other
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 8 Years to 12 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Anesthesia
Interventions: Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stroke, Motor Cortex; Lesion
Interventions: Rasch modified version of the Fugl-Meyer Motor assessment, Anatomical image acquisition, Functional MRI task and acquisition; Diagnostic Test
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: The Focus of This Study Are New Pulse Sequences.
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Pain
Interventions: ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Lymphoma
Interventions: Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 76 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: TI-Inhalation Powder A, TI-Inhalation Powder B; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hearing Loss
Interventions: Standard School Screening and Referral, Enhanced mHealth Screening, Specialty Telemedicine Referral; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 11 Years
Enrollment: 18,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lyme Disease
Interventions: T-Detect Lyme; Diagnostic Test
Lead sponsor: Adaptive Biotechnologies; Industry
Eligibility: 7 Years and older
Enrollment: 893 participants
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Danbury, Connecticut • Macon, Georgia • Savannah, Georgia + 29 more

Conditions: Healthy
Interventions: Canagliflozin/Placebo Placebo/Canagliflozin, no intervention; Drug · Other
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Breast Cancer
Interventions: Non-contrast DWI, Non-contrast MRI; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 269 participants
Timeline: 2018 – 2029
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Psychological Stress
Interventions: Primal Reflex Release Technique (PRRT); Other
Lead sponsor: University of Idaho; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Moscow, Idaho

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Abiraterone acetate (Treatment A), Abiraterone acetate (Treatment B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Genetic Disease
Interventions: Whole genome sequencing, BeginNGS test, WES; Genetic
Lead sponsor: Rady Pediatric Genomics & Systems Medicine Institute; Other
Eligibility: 1 Day to 10 Days
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy

Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

Retention of Whole-body Training Effects on Ambulatory Function in Children With Cerebral Palsy

Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Imaging Laterality in Chronic Stroke Patients

Clinical Testing of New MR Pulse Sequences

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky

ImmuneSense Lyme Study

A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

Non-contrast DWI for Supplemental Screening

Can a Novel Manual Therapy Technique Help Relieve Stress? Assessing Effects of Primal Reflex Release on the Body's Stress Response

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

Newborn Genomic Sequencing Pilot Study